Keywords: fda, rejects, forest, lexapro, anxiety, drug, development

US FDA rejects Forest's Lexapro for anxiety

Article | 11 April 2005

Print This

Drug development firm Forest Labs has had its application to market the antidepresssant Lexapro (escitalopram oxalate) as a treatment for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in